So what hap­pened with No­var­tis Gene Ther­a­pies? Here's your an­swer

4 years ago
People
Bioregnum

Take­da snaps up the Japan­ese rights to an old Shire cast-off; Boehringer In­gel­heim ac­quires Abexxa Bi­o­log­ics

4 years ago
News Briefing

Aerie fires CEO af­ter lead pro­gram flop, com­ments about pri­ma­ry end­points be­ing 'not re­quired'

4 years ago
People
Pharma

Covid-19 roundup: J&J boost­er shot da­ta show promise; CD­C's ACIP meet­ing this week to dis­cuss Pfiz­er boost­ers

4 years ago
Coronavirus

When ef­fi­ca­cy is bor­der­line: FDA needs to get more con­sis­tent on close-call drug ap­provals, agency-fund­ed re­search ...

4 years ago
FDA+

Af­ter sell­ing to Genen­tech, the old Je­cure team is back at an RNA-fo­cused start­up — and more en­thu­si­as­tic than ever

4 years ago
Financing
Startups

Ver­ri­ca hits an­oth­er bump in the road with CMO re­lat­ed let­ter from FDA

4 years ago
FDA+
Manufacturing

With plans to spend $360M, As­traZeneca will build its first-ever man­u­fac­tur­ing site in Ire­land

4 years ago
Manufacturing

Who are the women su­per­charg­ing bio­phar­ma R&D? Nom­i­nate them for this year's spe­cial re­port

4 years ago
Editor's note

Div­ing deep­er in­to in­her­it­ed reti­nal dis­or­ders, No­var­tis gob­bles up an­oth­er bite-sized op­to­ge­net­ics biotech

4 years ago
Deals
Cell/Gene Tx

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

4 years ago
FDA+

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer ...

4 years ago
Bioregnum

Ex­elix­is pulls a sur­prise win in thy­roid can­cer just days ahead of fi­nal Cabome­tyx read­out

4 years ago
R&D
FDA+

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

4 years ago
Cell/Gene Tx

Den­mark's Gubra to col­lab­o­rate with Bay­er on pep­tides; Sam­sung and Bio­gen re­ceive FDA ap­proval for Lu­cen­tis ...

4 years ago
News Briefing

Ex-My­lan em­ploy­ee pleads guilty to in­sid­er trad­ing, il­le­gal­ly deal­ing on FDA ap­provals, earn­ings and Up­john merg­er

4 years ago
Pharma

Time for round 2: Il­lu­mi­na-backed VC snags $325M for its next fund

4 years ago
Financing

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

4 years ago
R&D
In Focus

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

4 years ago
Financing

Covid-19 roundup: In­dia to re­sume vac­cine ex­ports as its own cam­paign is un­der con­trol; Pfiz­er to file for vac­cine OK ...

4 years ago
R&D

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

4 years ago
People

Months af­ter a mam­moth raise, Ven­tyx Bio­sciences dips back in­to ven­ture well

4 years ago
Financing

Mi­rati tri­umphs again in KRAS-mu­tat­ed lung can­cer with a close­ly watched FDA fil­ing now in the cards

4 years ago
R&D

The best of the rest: High­lights from the be­low-the-fold pre­sen­ta­tions at #ES­MO21

4 years ago
R&D
First page Previous page 637638639640641642643 Next page Last page
A service from the Financial Times